" class="no-js "lang="en-US"> Coave Therapeutics - Pharmtech Focus
Tuesday, January 31, 2023
Coave Therapeutics | Pharmtech Focus

Coave Therapeutics

About Coave Therapeutics

Coave Therapeutics

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

Related Story

Coave Therapeutics Strengthens Leadership Team with the Appointments of Catherine Mathis as Vice President Regulatory Affairs and Julien Berger as Head of Legal Affairs

September 6 2022

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS […]

Coave Therapeutics Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Next-generation Gene Therapies Targeting CNS Diseases

June 30 2022

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS […]

ABL and Coave Therapeutics Collaborate to Develop Manufacturing Processes and Create Joint Capabilities for Process Development

June 10 2022

Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS […]

Coave Therapeutics Strengthens Leadership Team with the Appointments of Thomas Blaettler MD as Chief Medical Officer and Patricia Françon PhD as Chief Operating Officer

November 15 2021

Coave Therapeutics (‘Coave‘), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare […]

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

July 21 2021

Coave Therapeutics (pronounced ‘cove’; formerly Horama), a clinical stage biotechnology company focused on developing life […]